ArticleInternational journal of molecular and cellular medicine2025
Association of RAGE gene polymorphisms (rs2070600 and rs2071288) with bone metabolism disturbances in patients with chronic kidney disease.
Article in International journal of molecular and cellular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is frequently accompanied by disturbances in bone metabolism, leading to a heightened risk of fractures. The receptor for advanced glycation end-products (RAGE) plays a pivotal role in the pathogenesis of CKD. This case-control study included 50 CKD patients and 50 healthy controls to examine the association between RAGE gene polymorphisms (rs2070600 and rs2071288) and bone metabolism markers. Serum parathyroid hormone (PTH), alkaline phosphatase (ALP), and vitamin D levels were measured as indicators of bone metabolism. CKD patients exhibited significantly higher ALP (317.54 ± 21.95 U/L) and PTH (331.33 ± 17.11 pg/mL) levels, along with lower vitamin D (26.92 ± 6.64 ng/mL) compared to controls (all P < 0.05). The CC genotype of rs2070600 was more prevalent among patients (52%) and was associated with an increased risk of CKD (OR = 2.79, 95% CI: 1.21-6.39, P = 0.014). In contrast, no significant association was found between rs2071288 and CKD risk. Notably, individuals carrying CC or CT genotypes for rs2070600 and rs2071288 had higher levels of PTH and ALP, alongside significantly lower levels of vitamin D. The RAGE gene's rs2070600 polymorphism may be connected to abnormalities in bone metabolism and the advancement of CKD. These results indicate that rs2070600 genotyping may be useful in identifying high-risk patients; however, additional research is required to validate its clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.